Prescribing patterns and safety monitoring of duloxetine using the Danish Register of Medicinal Product Statistics as a source

Scandinavian Journal of Public Health

Volumn 41, Issue 8, 2013, Pages 866-873

  Johansen, Anja Nygaard ^a   Stenzhorn, Annette Aalykke ^a   Thirstrup, Steffen ^a   Rosenzweig, Mary ^b   Gazerani, Parisa ^b  

^a AALBORG UNIVERSITY   (Denmark)

^b Danish Health and Medicines Authority   (Denmark)

Author keywords

Cymbalta ; Danish Health and Medicines Authority (DHMA); drug utilisation; duloxetine; marketed drugs; pattern of drug utilisation; Register of Medicinal Product Statistics (RMPS); safety monitoring; Xeristar

Indexed keywords

ANTIDEPRESSANT AGENT; DULOXETINE; THIOPHENE DERIVATIVE;

ADOLESCENT; ADULT; AGED; CHILD; CLINICAL PRACTICE; DENMARK; DEPRESSION; DRUG MONITORING; FEMALE; HUMAN; MALE; MIDDLE AGED; PRESCHOOL CHILD; REGISTER; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; YOUNG ADULT; ARTICLE; CYMBALTA®; DANISH HEALTH AND MEDICINES AUTHORITY (DHMA); DRUG UTILIZATION; MARKETED DRUGS; PATTERN OF DRUG UTILISATION; REGISTER OF MEDICINAL PRODUCT STATISTICS (RMPS); SAFETY MONITORING; STATISTICS; XERISTAR®;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; CHILD; CHILD, PRESCHOOL; DENMARK; DEPRESSION; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; REGISTRIES; RETROSPECTIVE STUDIES; THIOPHENES; YOUNG ADULT;

CYMBALTA®; DANISH HEALTH AND MEDICINES AUTHORITY (DHMA); DRUG UTILISATION; DULOXETINE; MARKETED DRUGS; PATTERN OF DRUG UTILISATION; REGISTER OF MEDICINAL PRODUCT STATISTICS (RMPS); SAFETY MONITORING; XERISTAR®;

EID: 84888194886     PISSN: 14034948     EISSN: 16511905     Source Type: Journal    
DOI: 10.1177/1403494813496599     Document Type: Article

References (22)

1. Bate A. Lindquist M. Edwards I.R. The application of knowledge discovery in databases to post-marketing drug safety: example of the WHO database. Fundam Clin Pharmacol 2008;22:127–40.
2. Bahri P. Tsintis P. Waller P.C. Regulatory pharmacovigilance in the EU. In: Ed. Mann R.D. Andrews E.B. (eds). Pharmacovigilance, 2nd ed. West Sussex: John Wiley & Sons Ltd, 2007, pp. 185–98.
3. Glasser S.P. Salas M. Delzell E. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems. J Clin Pharmacol 2007;47:1074–86.
4. Harmark L. van Grootheest A.C. Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol 2008;64:743–52.
5. Kimland E. Odlind V. Off-label drug use in pediatric patients. Clin Pharmacol Ther;91:796–801.
6. World Health Organization. The importance of pharmacovigilance. Geneva: WHO, 2002.
7. Strom B.L. Kimmel S.E. Hennessy S. The future of pharmacoepidemiology. In: Ed. Strom B.L. Kimmel S.E. Hennessy S. (eds). Pharmacoepidemiology, 5th ed. Wiley-Blackwell, 2012, pp. 893–95.
8. Wise L. Parkinson J. Raine J. et al. New approaches to drug safety: a pharmacovigilance tool kit. Nat Rev Drug Discov 2009;8:779–82.
9. Health and Medicines Authority. Licensing of medicines, http://laegemiddelstyrelsen.dk/en/topics/authorisation-and-supervision/licensing-of-medicines (accessed 6 January 2012).
10. Health and Medicines Authority. Marketing authorisation, http://laegemiddelstyrelsen.dk/en/topics/authorisation-and-supervision/licensing-of-medicines/marketing-authorisation (accessed 10 February 2012).
11. Health and Medicines Authority. Registration and monitoring of side effects, http://laegemiddelstyrelsen.dk/en/topics/side-effects-and-trials/side-effects/registration-and-monitoring (accessed 14 February 2012).
12. Health and Medicines Authority. Side effects, http://laegemiddelstyrelsen.dk/en/topics/side-effects-and-trials/side-effects (accessed 15 February 2012).
13. MEDSTAT, http://www.medstat.dk/da/view/datagrundlag_og_beskrivelse (accssed 19 December 2011).
14. European Medicines Agency, http://www.ema.europa.eu/ema/ (accessed 9 December 2011).
15. Kildemoes H.W. Sorensen H.T. Hallas J. The Danish National Prescription Registry. Scand J Public Health 2011;39(7 Suppl):38–41.
16. Register of Medicinal Product Statistics, http://www.ssi.dk/English/Health DataandICT/Health%20data/Registries/Register%20of%20Medicinal%20Products%20Statistics.aspx
17. Furu K. Wettermark B. Andersen M. et al. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 2010;106:86–94.
18. Statens Serum Institut. Forbruget af antidepressiva 2001–2011, http://www.ssi.dk/Sundhedsdataogit/Analyser%20og%20rapporter/Lagemiddelforbrugsanalyser/2012/Antidepressiva.aspx (accessed 10 May 2012).
19. Oedegaard K.J. Riise T. Dilsaver S.C. et al. A pharmaco-epidemiological study of migraine and antidepressant medications: complete one year data from the Norwegian population. J Affect Disord 2011;129:198–204.
20. Sundell K.A. Gissler M. Petzold M. et al. Antidepressant utilization patterns and mortality in Swedish men and women aged 20–34 years. Eur J Clin Pharmacol 2011;67:169–78.
21. Kornstein S.G. McEnany G. Enhancing pharmacologic effects in the treatment of depression in women. J Clin Psychiatry 2000;61 (Suppl 11):18–27.
22. Wittchen H.U. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety 2002;16:162–71.